CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®

  • Posted by: BIOCON

Biocon Included in S&P Global Sustainability Yearbook 2024

  • Posted by: BIOCON

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

  • Posted by: BIOCON

Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr Pre-Paid USD 200 Mn towards Debt Reduction

  • Posted by: BIOCON

Oral Cancer Task Force’s Consensus Guidelines for Head & Neck Cancer Recognized Among 13 Worldwide Clinical Practice Guidelines

  • Posted by: BIOCON

Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan

  • Posted by: BIOCON

Biocon Academy Conducts its 8th Graduation Day

  • Posted by: BIOCON

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

  • Posted by: BIOCON

Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year

  • Posted by: BIOCON

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>